A 52-year-old man from Delhi presents with a 3-month history of epigastric pain that wakes him at night. He reports black, tarry stools for the past week and denies vomiting. He takes aspirin 500 mg daily for knee pain and denies alcohol use. On examination, he appears pale; heart rate 102/min, blood pressure 118/76 mmHg. Hemoglobin is 9.2 g/dL (normal 13.5–17.5). Fecal occult blood test is positive. Upper endoscopy reveals a 1.5 cm ulcer on the anterior wall of the first part of the duodenum with a visible vessel at the base. What is the most appropriate next step in management?

Explanation

## Clinical Scenario Analysis This patient has an **actively bleeding duodenal ulcer** with hemodynamic stability but significant anemia (Hb 9.2 g/dL) and melena. The visible vessel at the ulcer base is a **Forrest Ia/Ib lesion** — high risk for rebleeding. ## Management Algorithm for Bleeding Peptic Ulcer ```mermaid flowchart TD A[Bleeding peptic ulcer on endoscopy]:::outcome --> B{Hemodynamic stability?}:::decision B -->|Unstable| C[Resuscitate, ICU care]:::action B -->|Stable| D{Forrest classification?}:::decision D -->|Ia/Ib/IIa: Visible vessel| E[Endoscopic hemostasis]:::action D -->|IIb/III: No vessel| F[PPI + supportive care]:::action E --> G[Adrenaline + heater probe/clip]:::action G --> H[IV PPI high-dose]:::action H --> I[Monitor, repeat endoscopy if rebleed]:::outcome C --> H ``` ## Why Endoscopic Hemostasis? **Key Point:** Forrest Ia/Ib lesions (spurting or oozing visible vessel) require **dual-modality endoscopic therapy** — injection (adrenaline 1:10,000) followed by thermal (heater probe) or mechanical (clip) hemostasis. This reduces rebleeding from ~50% (medical alone) to ~10–15%. **High-Yield:** High-dose IV PPI (omeprazole 40 mg IV BD or pantoprazole 80 mg bolus + 8 mg/hr infusion) must accompany endoscopy: - Raises intragastric pH > 6, promoting clot stability - Reduces rebleeding risk by ~50% - Mandatory for 72 hours post-hemostasis ## Why NOT the Other Options? | Option | Reason | | --- | --- | | Elective surgical repair | Surgery is reserved for **failed endoscopic hemostasis** (2 attempts) or massive transfusion requirement (>6 units). This patient is stable and has not had endoscopic therapy yet. | | Oral PPI + discharge | Oral therapy is insufficient for acute bleeding. IV PPI + endoscopic hemostasis is the standard of care. Discharging without hemostasis risks catastrophic rebleeding. | | Antrectomy + vagotomy | Surgical approach is obsolete in the PPI era. Indicated only if endoscopy fails or patient is unfit for repeated endoscopy. | **Clinical Pearl:** The **visible vessel** is the single strongest predictor of rebleeding. Patients with Forrest Ia/Ib lesions who do NOT receive endoscopic therapy have rebleeding rates >50%; with therapy, <15%. This is why endoscopy is **mandatory** here. **Mnemonic — NSAID Ulcer Management: "HEMOSTASIS-PPI"** - **H**emostasis (endoscopic, dual-modality) - **E**radication (H. pylori if positive; stop NSAID) - **M**onitoring (repeat endoscopy if rebleed) - **O**meprazole (high-dose IV) - **S**upport (transfusion, fluids) - **T**herapy (PPI long-term) - **A**void NSAIDs (or use with PPI) - **S**urgery (only if endoscopy fails) - **I**nvestigate (H. pylori, NSAID use) - **S**table follow-up (outpatient endoscopy if rebleed) [cite:Harrison 21e Ch 297]